Octreotide
1
Reactions 1285 - 23 Jan 2010 S Octreotide Dyspnoea, throat angioedema and urticaria successfully managed with desensitisation: case report A 58-year-old man experienced two separate allergic reactions, consisting of shortness of breath, throat angioedema and urticaria, during treatment with octreotide [Sandostatin; dosages and durations of therapy to reaction onsets not stated]. He subsequently underwent successful desensitisation to octreotide. The man had widely metastatic carcinoid syndrome that was refractory to radiation, chemotherapy and surgery. He had severe flushing episodes which only seemed to respond to octreotide; however, he developed allergy to octreotide after two long but interrupted courses. He experienced two identical allergic reactions, approximately 3 years apart, including dyspnoea, throat angioedema and urticaria within seconds of injecting SC octreotide. He was hospitalised for both reactions [treatment not stated]. Because of the man’s poor quality of life, he wanted to restart octreotide. He underwent desensitisation starting at 0.00004µg intravenously, and increasing approximately every 15 minutes by a factor of 10 with a final dose of 400µg intravenously. He was successfully desensitised, and was able to take SC octreotide 400µg daily; subsequently, his quality of life greatly improved. Van Lancker JA. DESENSITIZATION TO SANDOSTATIN (OCTREOTIDE) IN A PATIENT WITH CARCINOID SYNDROME. 2009 Annual Meeting of the American College of Allergy, Asthma and Immunology : abstr. P177, 5 Nov 2009. Available from: URL: http://www.acaai.org - USA 803004699 1 Reactions 23 Jan 2010 No. 1285 0114-9954/10/1285-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
-
Upload
hoangnguyet -
Category
Documents
-
view
214 -
download
2
Transcript of Octreotide
Reactions 1285 - 23 Jan 2010
SOctreotide
Dyspnoea, throat angioedema and urticariasuccessfully managed with desensitisation: casereport
A 58-year-old man experienced two separate allergicreactions, consisting of shortness of breath, throatangioedema and urticaria, during treatment with octreotide[Sandostatin; dosages and durations of therapy to reactiononsets not stated]. He subsequently underwent successfuldesensitisation to octreotide.
The man had widely metastatic carcinoid syndrome thatwas refractory to radiation, chemotherapy and surgery. Hehad severe flushing episodes which only seemed torespond to octreotide; however, he developed allergy tooctreotide after two long but interrupted courses. Heexperienced two identical allergic reactions, approximately3 years apart, including dyspnoea, throat angioedema andurticaria within seconds of injecting SC octreotide. He washospitalised for both reactions [treatment not stated].
Because of the man’s poor quality of life, he wanted torestart octreotide. He underwent desensitisation starting at0.00004µg intravenously, and increasing approximatelyevery 15 minutes by a factor of 10 with a final dose of400µg intravenously. He was successfully desensitised,and was able to take SC octreotide 400µg daily;subsequently, his quality of life greatly improved.Van Lancker JA. DESENSITIZATION TO SANDOSTATIN (OCTREOTIDE) INA PATIENT WITH CARCINOID SYNDROME. 2009 Annual Meeting of theAmerican College of Allergy, Asthma and Immunology : abstr. P177, 5 Nov 2009.Available from: URL: http://www.acaai.org - USA 803004699
1
Reactions 23 Jan 2010 No. 12850114-9954/10/1285-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
